Health Corner

GLP-1 agonists – A new era of weight loss

GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes and help treat obesity.
Weight gain remains a significant health issue as it is linked to numerous chronic conditions like type 2 diabetes, heart disease, high blood pressure, and certain cancers, as well as physical problems such as sleep apnea and osteoarthritis. Excess weight can also negatively impact mental health, leading to conditions like depression and anxiety. Lifestyle habits, such as where you eat, live, work, play, and worship, play a key role in shaping your body weight and health. Not getting enough sleep is also linked to weight gain. Not getting enough sleep may make you feel hungrier, consume more calories, and be more likely to choose unhealthy foods and beverages instead of healthier options.

There are various medications available now that can reduce appetite and make you feel full by acting on the brain and slowing stomach emptying. Weight-loss medications, such as those approved by the FDA, like semaglutide (Ozempic, Wegovy) and tirzepatide (Zep- bound), top the list for their ability to suppress appetite or alter fat absorption. Prescription medications are typically used for individuals with obesity or who are overweight and have other weight-related conditions. Some medi- cines, like phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave), com- bine two drugs that target appetite control, cravings, and brain function.

What are GLP-1 agonists?
GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes and help treat obesity. FDA-approved GLP-1 medication called Zepbound (tirzepatide) can improve moderate to severe sleep apnea, particularly in individuals with obesity, primarily by causing weight loss that reduces airway obstruction. GLP-1 agonists are most often injectable medications, meaning you inject liquid medica- tion with a needle and syringe. GLP-1 agonists are not safe to take during pregnancy. Animal studies show that these medications cause developmental abnormalities in the fetus. If you are able to become pregnant, you should use effective and reliable birth control while taking a GLP-1 agonist. If you become pregnant while taking the medication, see your healthcare provider immediately.

There is also a similar class of medications called dual GLP-1/GIP receptor agonists. There is currently one of these medications on the market: tirzepatide (Mounjaro®).

GLP-1 agonists for obesity
The FDA currently approves the use of semaglutide and high-dose liraglutide for the treatment of obesity. This is because these GLP-1 agonists have weight loss effects.

How often do you take GLP-1 agonists?
Your healthcare provider will tell you when and how often to take your medi- cation (usually injections). Be sure to follow their instructions. However, in general, the frequencies of the injections are:

•Dulaglutide: once a week
•Exenatide: twice a day
•Exenatide extended release: once a week
•Liraglutide: once a day
•Lixisenatide: once a day
•Semaglutide: once a week
•Tirzepatide: once a week
•Semaglutide tablets: daily

What are the potential benefits of GLP-1 agonists?

•Lowering blood pressure
•Improving lipid disorders
•Improving fatty liver disease
•Reducing your risk of heart disease and kidney disease
•Delaying the progression of diabe- tes-related nephropathy
•Reduced symptoms of depression and anxiety
•Improved mood and cognitive function, which may help with alcohol and substance use disorders by targeting the brain’s dopamine reward system
•May lower the risk of specific cancers, like endometrial and ovarian cancers

Dr. Jasmin Jacob<br> Dallas, USA

Dr. Jasmin Jacob
Dallas, USA

Dr. Jasmine Jacob is a family nurse practitioner specializing in neurology/sleep medicine. She is currently working in a state county hospital in Dallas, Texas. Her expertise includes a variety of sleep disorders, insomnia, narcolepsy, and neuromuscular disorders.

If you enjoyed this article, share it to reach a wider audience.

Facebook
Twitter
LinkedIn
Telegram

Related Posts

Rate this article
Rated 5 out of 5

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest News

Social Sharing

YouTube

Currently Playing
ADVERTISEMENT